

Table S3. Odds ratios and 95% confidence intervals of 17 treatment modalities under six end indicators according to the network meta-analysis.

SD

Chemotherapy	1.12 (0.78, 1.54)	0.69 (0.49, 0.98)	0.77 (0.49, 1.20)	0.88 (0.49, 1.51)	1.05 (0.54, 1.94)	0.82 (0.20, 3.49)	1.52 (0.64, 3.65)	1.02 (0.45, 2.21)	0.38 (0.15, 0.98)	0.83 (0.29, 2.25)	0.93 (0.34, 2.52)	1.01 (0.35, 2.88)	0.98 (0.43, 2.32)	0.90 (0.42, 1.98)	1.18 (0.45, 3.04)	1.55 (0.63, 3.74)		
0.90 (0.65, 1.28)	Bevacizumab+Chemotherapy	0.62 (0.42, 0.94)	0.69 (0.42, 1.17)	0.79 (0.44, 1.41)	0.94 (0.56, 1.60)	0.73 (0.17, 3.30)	1.37 (0.54, 3.53)	0.91 (0.45, 1.84)	0.34 (0.13, 0.95)	0.75 (0.25, 2.19)	0.83 (0.29, 2.37)	0.91 (0.30, 2.74)	0.89 (0.36, 2.21)	0.81 (0.38, 1.86)	1.06 (0.45, 2.55)	1.39 (0.61, 3.19)		
1.44 (1.02, 2.05)	1.61 (1.06, 2.39)	Cetuximab+Chemotherapy	1.11 (0.63, 1.96)	1.27 (0.66, 2.28)	1.52 (0.77, 2.91)	1.18 (0.27, 5.34)	2.20 (0.87, 5.68)	1.47 (0.65, 3.31)	0.54 (0.20, 1.48)	1.20 (0.40, 3.45)	1.34 (0.46, 3.87)	1.42 (0.58, 3.66)	1.29 (0.66, 2.64)	1.70 (0.64, 4.55)	2.23 (0.89, 5.48)			
1.30 (0.83, 2.05)	1.45 (0.86, 2.40)	0.90 (0.51, 1.60)	Panitumumab+Chemotherapy	1.14 (0.57, 2.26)	1.36 (0.65, 2.82)	1.06 (0.24, 4.98)	1.97 (0.75, 5.32)	1.31 (0.55, 3.10)	0.49 (0.17, 1.40)	1.07 (0.35, 3.26)	1.20 (0.40, 3.59)	1.31 (0.41, 4.11)	1.28 (0.50, 3.40)	1.17 (0.48, 2.91)	1.54 (0.54, 4.27)	2.01 (0.76, 5.33)		
1.14 (0.66, 2.03)	1.27 (0.71, 2.27)	0.79 (0.42, 1.51)	0.88 (0.44, 1.75)	Sunitinib+Chemotherapy	1.20 (0.54, 2.64)	0.94 (0.21, 4.50)	1.73 (0.64, 4.93)	1.16 (0.47, 2.84)	0.43 (0.15, 1.29)	0.94 (0.30, 2.98)	1.05 (0.34, 3.24)	1.15 (0.35, 3.85)	1.13 (0.42, 3.22)	1.03 (0.41, 2.71)	1.36 (0.46, 3.88)	1.76 (0.65, 4.84)		
0.95 (0.52, 1.84)	1.06 (0.62, 1.79)	0.66 (0.34, 1.30)	0.73 (0.36, 1.54)	Cediranib+Chemotherapy	0.79 (0.38, 1.85)	1.45 (0.50, 4.24)	0.98 (0.40, 2.28)	0.36 (0.12, 1.12)	0.79 (0.24, 2.62)	0.88 (0.28, 2.85)	0.94 (0.34, 2.26)	0.86 (0.34, 2.32)	1.13 (0.41, 3.15)	1.47 (0.57, 3.95)				
1.22 (0.29, 5.07)	1.36 (0.30, 5.76)	0.85 (0.19, 3.66)	0.94 (0.20, 4.10)	1.07 (0.22, 4.88)	Celecoxib+Chemotherapy	1.85 (0.33, 10.11)	1.25 (0.23, 6.21)	0.46 (0.08, 2.52)	1.02 (0.18, 5.35)	1.12 (0.19, 6.10)	1.24 (0.20, 6.93)	1.21 (0.23, 6.18)	1.10 (0.21, 5.53)	1.44 (0.24, 7.90)	1.89 (0.34, 10.14)			
0.66 (0.27, 1.57)	0.73 (0.28, 1.84)	0.46 (0.18, 1.15)	0.51 (0.19, 1.34)	0.58 (0.20, 1.56)	0.69 (0.24, 1.99)	0.54 (0.10, 2.99)	Sorafenib+Chemotherapy	0.67 (0.20, 2.10)	0.25 (0.07, 0.89)	0.54 (0.14, 2.09)	0.61 (0.16, 2.22)	0.66 (0.17, 2.59)	0.60 (0.18, 1.93)	0.78 (0.21, 2.77)	1.01 (0.29, 3.56)			
0.98 (0.45, 2.21)	1.09 (0.54, 2.20)	0.68 (0.30, 1.55)	0.76 (0.32, 1.81)	0.86 (0.35, 2.15)	1.02 (0.44, 2.52)	0.80 (0.16, 4.30)	1.50 (0.48, 5.04)	Axitinib+Chemotherapy	0.37 (0.11, 1.28)	0.81 (0.23, 3.04)	0.91 (0.26, 3.35)	0.99 (0.27, 3.64)	0.97 (0.32, 3.14)	0.88 (0.32, 2.65)	1.17 (0.47, 2.92)	1.51 (0.55, 4.64)		
2.65 (1.02, 6.89)	2.95 (1.05, 7.90)	1.84 (0.67, 5.04)	2.05 (0.72, 5.85)	2.33 (0.77, 6.88)	2.19 (0.40, 12.59)	4.06 (1.12, 14.48)	2.71 (0.78, 9.12)	Trebananib+Chemotherapy	2.20 (0.55, 8.75)	2.47 (0.65, 9.50)	2.67 (0.65, 11.15)	2.64 (0.75, 9.22)	2.39 (0.72, 8.20)	3.18 (0.82, 11.99)	4.14 (1.11, 14.77)			
1.21 (0.44, 3.40)	1.34 (0.46, 3.99)	0.84 (0.29, 2.50)	0.93 (0.31, 2.83)	1.06 (0.34, 3.34)	1.27 (0.38, 4.17)	0.98 (0.19, 5.66)	1.85 (0.48, 6.96)	1.23 (0.33, 4.31)	Conatumumab+Chemotherapy	1.12 (0.27, 4.60)	1.22 (0.27, 5.18)	1.19 (0.33, 4.38)	1.09 (0.31, 3.89)	1.43 (0.35, 5.77)	1.87 (0.49, 7.28)			
1.08 (0.40, 2.94)	1.20 (0.42, 3.40)	0.74 (0.26, 2.17)	0.83 (0.28, 2.51)	0.95 (0.31, 2.94)	1.13 (0.35, 3.53)	1.63 (0.45, 6.33)	1.10 (0.30, 3.91)	0.41 (0.11, 1.54)	0.89 (0.22, 3.68)	0.94 (0.34, 2.78)	0.86 (0.34, 2.32)	1.13 (0.41, 3.15)	1.47 (0.57, 3.95)					
0.99 (0.35, 2.85)	1.10 (0.36, 3.33)	0.68 (0.23, 2.10)	0.76 (0.24, 2.44)	0.87 (0.26, 2.86)	1.04 (0.31, 3.51)	0.81 (0.14, 4.89)	1.51 (0.39, 5.90)	1.01 (0.27, 3.72)	0.37 (0.09, 1.54)	0.82 (0.19, 3.64)	0.92 (0.22, 3.85)	Gantumab+Chemotherapy	1.09 (0.26, 4.58)	1.06 (0.27, 5.50)	1.66 (0.44, 6.52)			
1.02 (0.43, 2.34)	1.13 (0.45, 2.76)	0.70 (0.27, 1.73)	0.78 (0.29, 1.98)	0.89 (0.31, 2.40)	1.06 (0.36, 2.97)	0.82 (0.16, 4.34)	1.55 (0.45, 5.13)	1.04 (0.32, 3.16)	0.38 (0.11, 1.34)	0.84 (0.23, 3.05)	0.94 (0.25, 3.44)	1.02 (0.26, 3.80)	Gefitinib+Chemotherapy	0.98 (0.26, 3.44)	1.18 (0.29, 4.74)	1.53 (0.40, 5.92)		
1.11 (0.51, 2.40)	1.24 (0.54, 2.66)	0.77 (0.38, 1.53)	0.86 (0.34, 2.08)	0.98 (0.37, 2.44)	1.17 (0.43, 2.90)	0.91 (0.18, 4.71)	1.68 (0.52, 5.41)	1.13 (0.38, 3.17)	0.42 (0.12, 1.40)	0.92 (0.26, 3.23)	1.03 (0.28, 3.67)	1.13 (0.29, 4.07)	1.10 (0.35, 3.59)	PB+Chemotherapy	0.91 (0.28, 2.87)	1.21 (0.33, 4.13)	1.57 (0.47, 5.19)	
0.85 (0.33, 2.20)	0.94 (0.39, 2.23)	0.59 (0.22, 1.56)	0.65 (0.23, 2.84)	0.74 (0.26, 2.17)	0.89 (0.32, 2.42)	0.69 (0.13, 4.11)	1.28 (0.36, 4.72)	0.86 (0.34, 2.13)	0.31 (0.08, 1.22)	0.70 (0.17, 2.86)	0.78 (0.20, 3.08)	0.85 (0.21, 3.49)	0.77 (0.23, 2.65)	BC+Chemotherapy	1.31 (0.38, 4.28)	1.72 (0.56, 5.27)		
0.65 (0.27, 1.58)	0.72 (0.31, 1.63)	0.45 (0.18, 1.13)	0.50 (0.19, 1.31)	0.57 (0.21, 1.55)	0.68 (0.25, 1.77)	0.53 (0.10, 2.91)	0.99 (0.28, 3.41)	0.66 (0.22, 1.83)	0.24 (0.07, 0.90)	0.53 (0.14, 2.02)	0.60 (0.15, 2.28)	0.65 (0.17, 2.50)	0.64 (0.19, 2.13)	AB+Chemotherapy	0.64 (0.19, 2.46)	0.58 (0.19, 1.80)	0.76 (0.22, 2.49)	CB+Chemotherapy

PD

Chemotherapy	0.51 (0.29, 0.77)	0.77 (0.44, 1.13)	0.69 (0.37, 1.15)	0.82 (0.36, 2.04)	0.63 (0.27, 1.39)	0.57 (0.06, 5.30)	0.72 (0.16, 3.10)	0.54 (0.17, 1.43)	1.69 (0.56, 5.38)	0.93 (0.26, 3.27)	0.56 (0.16, 2.40)	1.54 (0.39, 6.86)	0.53 (0.21, 1.36)	0.34 (0.12, 0.84)	0.37 (0.09, 1.50)	1.21 (0.29, 5.07)
1.96 (1.30, 3.48)	Bevacizumab+Chemotherapy	1.52 (0.87, 2.68)	1.38 (0.72, 2.73)	1.62 (0.69, 4.79)	1.22 (0.66, 2.61)	1.16 (0.11, 11.35)	1.44 (0.30, 6.98)	1.07 (0.42, 2.57)	3.37 (1.01, 12.15)	1.89 (0.47, 7.35)	1.12 (0.32, 5.75)	3.09 (0.78, 15.21)	1.05 (0.41, 3.30)	0.66 (0.24, 1.92)	0.72 (0.18, 2.81)	2.37 (0.66, 9.63)
1.29 (0.88, 2.27)	0.66 (0.37, 1.15)	Cetuximab+Chemotherapy	0.89 (0.45, 1.89)	1.08 (0.45, 3.22)	0.81 (0.36, 2.10)	0.77 (0.07, 7.26)	0.94 (0.21,									

0.72 (0.18, 3.11)	1.84 (0.42, 9.24)	0.92 (0.21, 4.32)	1.19 (0.25, 6.07)	0.67 (0.12, 4.11)	1.30 (0.23, 7.58)	0.23 (0.02, 2.56)	0.46 (0.06, 3.41)	1.00 (0.18, 6.23)	0.46 (0.06, 3.33)	Conatumumab+Chemotherapy	0.85 (0.12, 6.20)	0.58 (0.07, 4.67)	1.08 (0.16, 7.24)	1.54 (0.23, 11.45)	1.45 (0.22, 10.22)	1.63 (0.23, 12.64)
0.84 (0.21, 3.37)	2.14 (0.49, 9.91)	1.07 (0.24, 4.96)	1.38 (0.29, 6.78)	0.78 (0.15, 4.32)	1.51 (0.26, 8.90)	0.27 (0.02, 2.92)	0.53 (0.06, 3.98)	1.19 (0.21, 7.11)	0.54 (0.07, 3.76)	Ganitumab+Chemotherapy	0.67 (0.08, 5.17)	1.25 (0.19, 8.17)	1.81 (0.26, 12.97)	1.69 (0.26, 11.41)	1.91 (0.27, 14.37)	
1.26 (0.27, 6.28)	3.22 (0.62, 18.63)	1.62 (0.30, 8.92)	2.08 (0.36, 12.58)	1.16 (0.18, 7.99)	2.28 (0.34, 16.09)	0.41 (0.03, 5.09)	0.79 (0.09, 6.81)	1.79 (0.28, 12.57)	0.82 (0.10, 6.63)	Gefitinib+Chemotherapy	1.88 (0.25, 14.49)	2.68 (0.37, 22.20)	2.52 (0.35, 20.78)	2.85 (0.35, 25.68)		
0.66 (0.19, 2.35)	1.67 (0.45, 7.08)	0.84 (0.22, 3.44)	1.08 (0.26, 4.80)	0.61 (0.13, 3.01)	1.19 (0.24, 6.27)	0.22 (0.02, 2.12)	0.42 (0.06, 2.97)	0.92 (0.17, 5.10)	0.42 (0.07, 2.80)	PB+Chemotherapy	1.42 (0.23, 9.06)	1.33 (0.22, 8.52)	1.50 (0.23, 10.58)			
0.47 (0.12, 1.76)	1.19 (0.30, 4.96)	0.60 (0.17, 2.02)	0.77 (0.17, 3.45)	0.43 (0.08, 2.24)	0.85 (0.16, 4.32)	0.15 (0.01, 1.54)	0.30 (0.04, 2.17)	0.66 (0.12, 3.57)	0.30 (0.04, 1.94)	BC+Chemotherapy	0.94 (0.15, 5.98)	1.05 (0.16, 7.28)				
0.50 (0.13, 1.77)	1.27 (0.39, 4.28)	0.63 (0.16, 2.46)	0.82 (0.20, 3.50)	0.46 (0.10, 2.11)	0.89 (0.21, 3.98)	0.16 (0.01, 1.63)	0.31 (0.04, 2.19)	0.70 (0.22, 2.17)	0.32 (0.05, 2.00)	AB+Chemotherapy	1.12 (0.19, 6.97)					
0.44 (0.10, 1.77)	1.13 (0.30, 4.13)	0.56 (0.13, 2.40)	0.73 (0.15, 3.36)	0.41 (0.07, 2.08)	0.80 (0.16, 3.89)	0.14 (0.01, 1.57)	0.28 (0.03, 2.08)	0.62 (0.12, 3.00)	0.28 (0.04, 1.89)	CB+Chemotherapy	0.90 (0.14, 5.15)					

Notes: SD = stable disease; PD = progressive disease; CR = complete response; PR = partial response; ORR = overall response rate; DCR = disease control rate; PB=Panitumumab+Bevacizumab;BC=Brivanib+Cetuximab;AB=Axitinib+Bevacizumab;CB=Cetuximab+Bevacizumab;